Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...
Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flex...
Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network – Pr...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...
Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced a partnership to expand access to ...
The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for...
GenomOncology announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain canc...
Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...
The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for...
Moleculin Biotech, Inc., a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infecti...
© 2025 Biopharma Boardroom. All Rights Reserved.
